Proteolytic cascade in the amyloidogenesis of Alzheimer's disease.
beta-Amyloid, a neurotoxic peptide deposited in the brains of Alzheimer's disease patients, is released by a series of membrane-limited proteolytic events. beta-Secretase activity is enhanced by cellular targeting into intracellular cholesterol-rich microdomains, which are dispersed by statins.
Sidera
C
C
Department of Basic Medical Sciences, St. George's Hospital Medical School, Cranmer Terrace, London SW17 ORE, UK.
Parsons
R
R
Austen
B
B
D000544:Alzheimer Disease / Q000378:metabolism*; D053829:Amyloid Precursor Protein Secretases; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000736:Androstenes / Q000494:pharmacology; D016282:Aspartic Acid Endopeptidases; D002460:Cell Line; D002784:Cholesterol / Q000378:metabolism; D010450:Endopeptidases / Q000378:metabolism*; D005786:Gene Expression Regulation; D006031:Glycosylation; D006801:Humans; D006863:Hydrogen-Ion Concentration; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D015398:Signal Transduction
D016229:Amyloid beta-Peptides; D000736:Androstenes; C006261:3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one; D002784:Cholesterol; D053829:Amyloid Precursor Protein Secretases; D010450:Endopeptidases; D016282:Aspartic Acid Endopeptidases; C509280:BACE1 protein, human